secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001558370-25-010786
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics pays ~$225M upfront to cancel Censa sepiapterin royalty obligations
--------------------------------------------------------------------------------

- Upfront cash payment of ~$225M to former Censa securityholders eliminates 8-12% annual net sales royalties.
- Original milestones: 8% on sales ≤$250M, 10% on $250M-$500M, 12% on >$500M.
- Additional Milestone Payments up to $100M each (total $500M) based on cumulative net sales thresholds (e.g., $3B, $5B, $7B, $9B, $11B).
- Participation was ~90% of former Censa securityholders; remaining may join and receive pro rata consideration.
- Sepiapterin is the product; other merger obligations remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/0001558370-25-010786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025010786/tmb-20250805x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-010786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer